

Andreas E Kulozik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8116110/publications.pdf>

Version: 2024-02-01

139
papers

16,159
citations

43973

48
h-index

17055

122
g-index

143
all docs

143
docs citations

143
times ranked

21569
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic modifiers of fetal hemoglobin affect the course of sickle cell disease in patients treated with hydroxyurea. <i>Haematologica</i> , 2022, 107, 1577-1588.	1.7	6
2	Differential Analysis of the Nuclear and the Cytoplasmic RNA Interactomes in Living Cells. <i>Methods in Molecular Biology</i> , 2022, 2428, 291-304.	0.4	2
3	Constitutional PIGA mutations cause a novel subtype of hemochromatosis in patients with neurologic dysfunction. <i>Blood</i> , 2022, 139, 1418-1422.	0.6	8
4	Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. <i>Blood</i> , 2022, 140, 45-57.	0.6	22
5	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. <i>Leukemia</i> , 2022, 36, 1759-1768.	3.3	4
6	Germline RET variants underlie a subset of paediatric osteosarcoma. <i>Journal of Medical Genetics</i> , 2021, 58, 20-24.	1.5	7
7	Introduction of Universal Newborn Screening for Sickle Cell Disease in Germany – A Brief Narrative Review. <i>International Journal of Neonatal Screening</i> , 2021, 7, 7.	1.2	4
8	NMD inhibition by 5-azacytidine augments presentation of immunogenic frameshift-derived neoepitopes. <i>IScience</i> , 2021, 24, 102389.	1.9	22
9	The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. <i>Radiotherapy and Oncology</i> , 2021, 159, 8-16.	0.3	21
10	Blasticidin S inhibits mammalian translation and enhances production of protein encoded by nonsense mRNA. <i>Nucleic Acids Research</i> , 2021, 49, 7665-7679.	6.5	13
11	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	7.7	110
12	Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011 – 2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 4543.	1.0	3
13	Recommendations for diagnosis and treatment of methemoglobinemia. <i>American Journal of Hematology</i> , 2021, 96, 1666-1678.	2.0	56
14	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
15	Odisha Revisited: A Personal Account. <i>Frontiers in Medicine</i> , 2021, 8, 745337.	1.2	1
16	Does the world need germline editing for α -thalassemia?. <i>Haematologica</i> , 2021, , .	1.7	0
17	TP53 and KRAS Variants at Initial Diagnosis Identify an Ultra-High Risk Group of Pediatric T-Lymphoblastic Leukemia (T-ALL). <i>Blood</i> , 2021, 138, 1315-1315.	0.6	0
18	Summary of Joint European Hematology Association (EHA) and EuroBloodNet Recommendations on Diagnosis and Treatment of Methemoglobinemia. <i>HemaSphere</i> , 2021, 5, e660.	1.2	1

#	ARTICLE	IF	CITATIONS
19	Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. <i>Leukemia</i> , 2020, 34, 151-166.	3.3	53
20	Sickle cell disease in Germany: Results from a national registry. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28130.	0.8	20
21	Single-cell analysis of structural variations and complex rearrangements with tri-channel processing. <i>Nature Biotechnology</i> , 2020, 38, 343-354.	9.4	59
22	Prexasertib (LY2606368) reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and synergizes with cisplatin and talazoparib. <i>International Journal of Cancer</i> , 2020, 147, 1059-1070.	2.3	17
23	Gene Therapy of the Hemoglobinopathies. <i>HemaSphere</i> , 2020, 4, e479.	1.2	18
24	Chromatin accessibility landscape of pediatric T-cell lymphoblastic leukemia and human T-cell precursors. <i>EMBO Molecular Medicine</i> , 2020, 12, e12104.	3.3	13
25	(Phospho)proteomic Profiling of Microsatellite Unstable CRC Cells Reveals Alterations in Nuclear Signaling and Cholesterol Metabolism Caused by Frameshift Mutation of NMD Regulator UPF3A. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5234.	1.8	6
26	Low-frequency variation near common germline susceptibility loci are associated with risk of Ewing sarcoma. <i>PLoS ONE</i> , 2020, 15, e0237792.	1.1	6
27	2,6-Diaminopurine as a highly potent corrector of UGA nonsense mutations. <i>Nature Communications</i> , 2020, 11, 1509.	5.8	46
28	Plasticity of nuclear and cytoplasmic stress responses of RNA-binding proteins. <i>Nucleic Acids Research</i> , 2020, 48, 4725-4740.	6.5	40
29	Ageing of Preleukemic Thymocytes Drives CpG Island Hypermethylation in T-cell Acute Lymphoblastic Leukemia. <i>Blood Cancer Discovery</i> , 2020, 1, 274-289.	2.6	21
30	Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
31	Title is missing!. , 2020, 15, e0237792.		0
32	Title is missing!. , 2020, 15, e0237792.		0
33	Title is missing!. , 2020, 15, e0237792.		0
34	Title is missing!. , 2020, 15, e0237792.		0
35	The German National Registry of Primary Immunodeficiencies (2012–2017). <i>Frontiers in Immunology</i> , 2019, 10, 1272.	2.2	71
36	Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 713-716.	0.6	42

#	ARTICLE	IF	CITATIONS
37	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e026644.	0.8	27
38	Intracardiac Extension of Wilms Tumor: A Case of a 2.5-Year-Old Girl Presenting with Upper Venous Congestion Caused by Tumor Growth into the Right Cardiac Ventricle. <i>Case Reports in Oncology</i> , 2019, 12, 33-38.	0.3	3
39	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	7.7	65
40	<i>PTEN</i> abnormalities predict poor outcome in children with T-cell acute lymphoblastic leukemia treated according to ALL IC-BFM protocols. <i>American Journal of Hematology</i> , 2019, 94, E93-E96.	2.0	36
41	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
42	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	13.7	1,872
43	<i>PDX</i> models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	38
44	β -Thalassemia Mutations in Jamaica: Geographic Variation in Small Communities. <i>Hemoglobin</i> , 2018, 42, 294-296.	0.4	3
45	Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial. <i>British Journal of Haematology</i> , 2018, 183, 96-103.	1.2	16
46	MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF- κ B. <i>BMC Cancer</i> , 2018, 18, 663.	1.1	11
47	Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility. <i>Nature Communications</i> , 2018, 9, 3184.	5.8	50
48	Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 34, 271-285.e7.	7.7	48
49	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. <i>Leukemia</i> , 2018, 32, 1657-1669.	3.3	86
50	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, e26-e37.	0.6	195
51	Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	0.7	200
52	The epidemiology of sickle cell disease in Germany following recent large-scale immigration. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26550.	0.8	28
53	Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. <i>European Journal of Cancer</i> , 2017, 81, 1-8.	1.3	4
54	Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin. <i>Blood</i> , 2017, 130, 875-880.	0.6	42

#	ARTICLE	IF	CITATIONS
55	NOTCH1 mutation, TP53 alteration and myeloid antigen expression predict outcome heterogeneity in children with first relapse of T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2017, 102, e249-e252.	1.7	6
56	Newborn screening for severe combined immunodeficiency using a novel and simplified method to measure T-cell excision circles (TREC). <i>Clinical Immunology</i> , 2017, 175, 51-55.	1.4	20
57	Dual function of UPF3B in early and late translation termination. <i>EMBO Journal</i> , 2017, 36, 2968-2986.	3.5	89
58	Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL. <i>Blood</i> , 2017, 130, 2146-2149.	0.6	7
59	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. <i>Clinical Sarcoma Research</i> , 2017, 7, 9.	2.3	51
60	The INFORM personalized medicine study for high-risk pediatric cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10509-10509.	0.8	1
61	High expression of miR-125b-2 and SNORD116 noncoding RNA clusters characterize ERG-related B cell precursor acute lymphoblastic leukemia. <i>Oncotarget</i> , 2017, 8, 42398-42413.	0.8	19
62	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	2.1	14
63	Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. <i>Blood</i> , 2016, 127, 2101-2112.	0.6	208
64	The differential expression of alternatively polyadenylated transcripts is a common stress-induced response mechanism that modulates mammalian mRNA expression in a quantitative and qualitative fashion. <i>Rna</i> , 2016, 22, 1441-1453.	1.6	36
65	Exon Junction Complexes Show a Distributional Bias toward Alternatively Spliced mRNAs and against mRNAs Coding for Ribosomal Proteins. <i>Cell Reports</i> , 2016, 16, 1588-1603.	2.9	65
66	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	1.3	262
67	Haemoglobin Variant Screening in Jamaica: Meeting Student's Request. <i>British Journal of Haematology</i> , 2016, 172, 634-636.	1.2	10
68	Mutating heme oxygenase-1 into a peroxidase causes a defect in bilirubin synthesis associated with microcytic anemia and severe hyperinflammation. <i>Haematologica</i> , 2016, 101, e436-e439.	1.7	18
69	Therapy with low-dose azacitidine for MDS in children and young adults: a retrospective analysis of the EWOG-MDS study group. <i>British Journal of Haematology</i> , 2016, 172, 930-936.	1.2	31
70	Proteomic Analysis Reveals Branch-specific Regulation of the Unfolded Protein Response by Nonsense-mediated mRNA Decay. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 1584-1597.	2.5	28
71	Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screening. <i>Annals of Hematology</i> , 2016, 95, 397-402.	0.8	29
72	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	7.7	438

#	ARTICLE	IF	CITATIONS
73	<i>CRLF2</i> over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 59260-59272.	0.8	24
74	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. <i>Oncotarget</i> , 2016, 7, 61860-61873.	0.8	27
75	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. <i>Oncotarget</i> , 2016, 7, 66344-66359.	0.8	30
76	The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis. <i>Blood</i> , 2015, 125, 1159-1169.	0.6	18
77	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. <i>Blood</i> , 2015, 125, 2311-2313.	0.6	60
78	Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy. <i>Radiation Oncology</i> , 2015, 10, 146.	1.2	14
79	HIV-1 Recruits UPF1 but Excludes UPF2 to Promote Nucleocytoplasmic Export of the Genomic RNA. <i>Biomolecules</i> , 2015, 5, 2808-2839.	1.8	52
80	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	7.7	933
81	Establishment of a patient-derived orthotopic osteosarcoma mouse model. <i>Journal of Translational Medicine</i> , 2015, 13, 136.	1.8	35
82	Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. <i>Nature Communications</i> , 2015, 6, 8940.	5.8	242
83	The best of 25 years: mRNA 3' end processing. <i>Rna</i> , 2015, 21, 640-641.	1.6	0
84	Improved binding site assignment by high-resolution mapping of RNA-protein interactions using iCLIP. <i>Nature Communications</i> , 2015, 6, 7921.	5.8	32
85	A network of SMG-8, SMG-9 and SMG-1 C-terminal insertion domain regulates UPF1 substrate recruitment and phosphorylation. <i>Nucleic Acids Research</i> , 2015, 43, 7600-7611.	6.5	51
86	Pediatric T-cell lymphoblastic leukemia evolves into relapse by clonal selection, acquisition of mutations and promoter hypomethylation. <i>Haematologica</i> , 2015, 100, 1442-1450.	1.7	65
87	Mpl Gain-of-Function Mutations Can be Classified By Differential Subcellular Processing, Molecular Mechanisms, Mode of Inheritance and Clinical Impact. <i>Blood</i> , 2015, 126, 1634-1634.	0.6	1
88	Gene Panel Sequencing of Primary and Relapsed Pediatric T-ALL Shows That Relapse-Specific Mutations Are Diverse and Mostly Non-Recurrent. <i>Blood</i> , 2015, 126, 1428-1428.	0.6	0
89	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	7.7	627
90	Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 15-23.	0.3	39

#	ARTICLE	IF	CITATIONS
91	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	13.7	520
92	5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion. <i>EMBO Molecular Medicine</i> , 2014, 6, 1593-1609.	3.3	51
93	Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. <i>Blood</i> , 2014, 124, 106-110.	0.6	50
94	The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. <i>Haematologica</i> , 2014, 99, e188-e192.	1.7	114
95	NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2013, 98, 928-936.	1.7	81
96	Whole Exome Sequencing Identifies Novel Lysine-Missense Mutations In Incomplete Childhood Chediak-Higashi-Syndrome Presenting As Hemphagocytic Lymphohistiocytosis (HLH). <i>Blood</i> , 2013, 122, 3479-3479.	0.6	0
97	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	7.7	1,551
98	In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. <i>Radiation Oncology</i> , 2012, 7, 52.	1.2	27
99	Treatment of pediatric patients and young adults with particle therapy at the Heidelberg Ion Therapy Center (HIT): establishment of workflow and initial clinical data. <i>Radiation Oncology</i> , 2012, 7, 170.	1.2	44
100	Hereditary thrombocythemia caused by a thrombopoietin (THPO) gain-of-function mutation associated with multiple myeloma and congenital limb defects. <i>Annals of Hematology</i> , 2012, 91, 1129-1133.	0.8	11
101	A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL. <i>British Journal of Haematology</i> , 2012, 157, 180-187.	1.2	9
102	Gain-of-function mutations in interleukin-7 receptor-1 (IL7R) in childhood acute lymphoblastic leukemias. <i>Journal of Experimental Medicine</i> , 2011, 208, 901-908.	4.2	307
103	p38 MAPK Controls Prothrombin Expression by Regulated RNA 3' End Processing. <i>Molecular Cell</i> , 2011, 41, 298-310.	4.5	70
104	Stay Tuned: miRNA Expression and Nonsense-Mediated Decay in Brain Development. <i>Molecular Cell</i> , 2011, 42, 407-408.	4.5	9
105	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 763-774.	3.9	211
106	Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. <i>Radiation Oncology</i> , 2011, 6, 119.	1.2	14
107	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e348-e349.	0.8	2
108	Mechanism of escape from nonsense-mediated mRNA decay of human β -globin transcripts with nonsense mutations in the first exon. <i>Rna</i> , 2011, 17, 843-854.	1.6	120

#	ARTICLE	IF	CITATIONS
109	Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. <i>BMC Cancer</i> , 2010, 10, 96.	1.1	56
110	Enhancement of Radiation Response in Osteosarcoma and Rhabdomyosarcoma Cell Lines by Histone Deacetylase Inhibition. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 237-245.	0.4	87
111	NMD: RNA biology meets human genetic medicine. <i>Biochemical Journal</i> , 2010, 430, 365-377.	1.7	192
112	Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the <i>MYC</i> and <i>MYCN</i> Loci. <i>Journal of Clinical Oncology</i> , 2009, 27, 1627-1636.	0.8	274
113	The Hierarchy of Exon-Junction Complex Assembly by the Spliceosome Explains Key Features of Mammalian Nonsense-Mediated mRNA Decay. <i>PLoS Biology</i> , 2009, 7, e1000120.	2.6	114
114	Downregulation of Notch signaling by β -secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. <i>Annals of Hematology</i> , 2009, 88, 613-621.	0.8	27
115	Unusual bipartite mode of interaction between the nonsense-mediated decay factors, UPF1 and UPF2. <i>EMBO Journal</i> , 2009, 28, 2293-2306.	3.5	126
116	Long-term outcome after polychemotherapy and intensive local radiation therapy of high-grade osteosarcoma. <i>European Journal of Cancer</i> , 2009, 45, 2447-2451.	1.3	34
117	Disassembly of Exon Junction Complexes by PYM. <i>Cell</i> , 2009, 137, 536-548.	13.5	162
118	High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF- β and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. <i>Blood</i> , 2009, 114, 1053-1062.	0.6	105
119	Long-term remission of children with relapsed and secondary anaplastic large cell non-Hodgkin lymphoma (ALCL) following treatment with pulsed dexamethasone and low dose etoposide. <i>Pediatric Blood and Cancer</i> , 2008, 50, 126-129.	0.8	10
120	Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. <i>Pediatric Blood and Cancer</i> , 2008, 50, 683-687.	0.8	34
121	Interactions between UPF1, eRFs, PABP and the exon junction complex suggest an integrated model for mammalian NMD pathways. <i>EMBO Journal</i> , 2008, 27, 736-747.	3.5	269
122	Unexpected roles for UPF1 in HIV-1 RNA metabolism and translation. <i>Rna</i> , 2008, 14, 914-927.	1.6	83
123	The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the Nonsense Mediated Decay pathway. <i>Nucleic Acids Research</i> , 2007, 35, 4542-4551.	6.5	107
124	Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. <i>Journal of Clinical Investigation</i> , 2007, 117, 683-692.	3.9	252
125	The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. <i>European Journal of Human Genetics</i> , 2007, 15, 1156-1162.	1.4	102
126	The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile.. <i>Blood</i> , 2007, 110, 2789-2789.	0.6	0

#	ARTICLE	IF	CITATIONS
127	A chemiluminescence-based reporter system to monitor nonsense-mediated mRNA decay. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 186-191.	1.0	55
128	Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. <i>Blood</i> , 2006, 108, 1151-1157.	0.6	262
129	Internal ribosome entry sequence-mediated translation initiation triggers nonsense-mediated decay. <i>EMBO Reports</i> , 2006, 7, 722-726.	2.0	19
130	The uORF-containing thrombopoietin mRNA escapes nonsense-mediated decay (NMD). <i>Nucleic Acids Research</i> , 2006, 34, 2355-2363.	6.5	41
131	Functions of hUpf3a and hUpf3b in nonsense-mediated mRNA decay and translation. <i>Rna</i> , 2006, 12, 1015-1022.	1.6	112
132	The role of nonsense-mediated decay in physiological and pathological processes. , 2005, , .		0
133	Exon-Junction Complex Components Specify Distinct Routes of Nonsense-Mediated mRNA Decay with Differential Cofactor Requirements. <i>Molecular Cell</i> , 2005, 20, 65-75.	4.5	277
134	The Prothrombin C>T Mutation at Position 20209 (F2 20209*T) Promotes 3' end mRNA Processing and Thus Contributes to Thrombophilia through Gain-of-Function.. <i>Blood</i> , 2005, 106, 2145-2145.	0.6	0
135	Nonsense-mediated decay approaches the clinic. <i>Nature Genetics</i> , 2004, 36, 801-808.	9.4	546
136	Y14 and hUpf3b Form an NMD-Activating Complex. <i>Molecular Cell</i> , 2003, 11, 939-949.	4.5	258
137	Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. <i>Nature Genetics</i> , 2001, 28, 389-392.	9.4	247
138	Reversible central pontine and extrapontine myelinolysis in a 16-year-old girl. <i>Child's Nervous System</i> , 2001, 17, 294-296.	0.6	23
139	A Perfect Message. <i>Cell</i> , 1999, 96, 307-310.	13.5	789